top of page
High Res Laxxon Logo USE.png
Laxxon’s internal pipeline includes reformulating generic drugs for novel therapeutic applications, with intellectual property secured via technology transfer.
Laxxon - [screen printing (white)].png

Product Pipeline

Product

Indication

2025

2026

2027

2028

2029

LXM.1

Epilepsy

LXM.2

Diabetes / Metabolic Syndrome

LXM.4

Rheumatoid Arthritis

LXM.5

Parkinson's Disease

LXM.6

Renal Cell Carcinoma

LXM.10

Thromboembolism

LXM.12

Prostate Carcinoma

LXM.13

Attention-Deficit/

Hyperactivity Disorder

Key:

Formulation & Product Development

Pre-Clinical

Clinical & Registration
(based on bioequivalence studies)

Learn more about our internal and external pipelines

Wide array of Laxxon's 3D printed tablets
bottom of page